Anand Kumar

Dr. Anand Kumar

Faculty of Pharmacy, Khwaja Moinuddin Chishti Language University, Lucknow, Uttar Prasedh, India: Lucknow, Uttar Pradesh, IN, Lucknow, India
orcid
Assistant Professor of Pharmacology at Khwaja Moinuddin Chis...

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2023 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
STSunita Thakur
Sunita Thakur
MAMeraj Anjum
Meraj Anjum
SJShweta Jaiswal
Shweta Jaiswal
Anand KumarAnand Kumar
Anand Kumar
PDPayal Deepak
Payal Deepak
PRP.S. Rajinikanth
P.S. Rajinikanth

23 October 2023 in International Immunopharmacology
Verified
Journal Article
Closed access
RCRishabh Chaudhary
Rishabh Chaudhary
APAjay Prasad
Ajay Prasad
VAVipul Agarwal
Vipul Agarwal
MRMujeeba Rehman
Mujeeba Rehman
Anand KumarAnand Kumar
Anand Kumar
VMVikas Mishra
Vikas Mishra

18 October 2023 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
SJShweta Jaiswal
Shweta Jaiswal
MAMeraj Anjum
Meraj Anjum
STSunita Thakur
Sunita Thakur
PPPrashant Pandey
Prashant Pandey
DADilip Kumar Arya
Dilip Kumar Arya
PRParuvathanahalli Siddalingam Rajinikanth
Paruvathanahalli Siddalingam Rajinikanth

9 March 2023 in Current Molecular Pharmacology
Verified
Journal Article
Open access
PDF file
PPPriyanka Prajapati
Priyanka Prajapati
Anand KumarAnand Kumar
Anand Kumar
RCRishabh Chaudhary
Rishabh Chaudhary
SMSHUBHADA V MANGRULKAR
SHUBHADA V MANGRULKAR
MAMalti Arya
Malti Arya
SKSapana Kushwaha
Sapana Kushwaha
Background: As people age, physical impairments may have a deleterious role in skeletal muscles. Sarcopenia Clinical Practice Guidelines 2017 and the European Working Group on Sarcopenia in older people are two organizations that have published essential guidelines on the definition of “sarcopenia". Sarcopenia is a geriatric syndrome, characterized by skeletal muscle mass degeneration brought on by ageing, which lowers muscular function and quality. Moreover, sarcopenia can be classified as primary or age-associated sarcopenia and secondary sarcopenia. Also, secondary sarcopenia occurs when other diseases such as diabetes, obesity, cancer, cirrhosis, myocardial failure, chronic obstructive pulmonary disease, and inflammatory bowel disease also contribute to muscle loss. Furthermore, sarcopenia is linked with a high risk of negative outcomes, considering a gradual reduction in physical mobility, poor balance, and increased fracture risks which ultimately leads to poor quality of life. Objective: In this comprehensive review, we have elaborated on the pathophysiology, and various signaling pathways linked with sarcopenia. Also, discussed are the preclinical models and current interventional therapeutics to treat muscle wasting in older patients. Conclusion: In a nutshell, a comprehensive description of the pathophysiology, mechanisms, animal models, and interventions of sarcopenia. We also shed light on pharmacotherapeutics present in clinical trials which are being developed as potential therapeutic options for wasting diseases. Thus, this review could fill in the knowledge gaps regarding sarcopenia-related muscle loss and muscle quality for both researchers and clinicians.

1 November 2023 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
PDPayal Deepak
Payal Deepak
PKPraveen Kumar
Praveen Kumar
PPPrashant Pandey
Prashant Pandey
DADilip Kumar Arya
Dilip Kumar Arya
SJShweta Jaiswal
Shweta Jaiswal
PRP.S. Rajinikanth
P.S. Rajinikanth
Background: Antitumor research aims to efficiently target hepatocarcinoma cells (HCC) for drug delivery. Nanostructured lipid carriers (NLCs) are promising for active tumour targeting. Cell-penetrating peptides are feasible ligands for targeted cancer treatment. Methods: In this study, we optimized gefitinib-loaded NLCs (GF-NLC) for HCC treatment. The NLCs contained cholesterol, oleic acid, Pluronic F-68, and Phospholipon 90G. The NLC surface was functionalized to enhance targeting with the cRGDfK-pentapeptide, which binds to the αvβ 3 integrin receptor overexpressed on hepatocarcinoma cells. Results: GF-NLC formulation was thoroughly characterized for various parameters using differential scanning calorimetry and X-ray diffraction analysis. In-vitro and in-vivo studies on the HepG2 cell line showed cRGDfK@GF-NLC’s superiority over GF-NLC and free gefitinib. cRGDfK@GF-NLC exhibited significantly higher cytotoxicity, growth inhibition, and cellular internalization. Biodistribution studies demonstrated enhanced tumour site accumulation without organ toxicity. The findings highlight cRGDfK@GF-NLC as a highly efficient carrier for targeted drug delivery, surpassing non-functionalized NLCs. These functionalized NLCs offer promising prospects for improving hepatocarcinoma therapy outcomes by specifically targeting HCC cells. Conclusion: Based on these findings, cRGDfK@GF-NLC holds immense potential as a highly efficient carrier for targeted drug delivery of anticancer agents, surpassing the capabilities of non-functionalized NLCs. This research opens up new avenues for effective treatment strategies in hepatocarcinoma.

5 May 2023 in International Immunopharmacology
Verified
Journal Article
Closed access
ASArchana Bharti Sonkar
Archana Bharti Sonkar
PKPranesh Kumar
Pranesh Kumar
Anand KumarAnand Kumar
Anand Kumar
AGAnurag Kumar Gautam
Anurag Kumar Gautam
AVAbhishek Verma
Abhishek Verma
SSSudipta Saha
Sudipta Saha